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Abstract.  In mammalian  cells inhibition  of the cdc2 
function results in arrest in the G2-phase of the cell 
cycle.  Several cdc2-related gene products have been 
identified recently and it has been hypothesized that 
they control earlier cell cycle events.  Here we have 
studied the relationship  between activation  of one of 
these cdc2 homologs,  the cdk2 protein  kinase,  and the 
progression  through  the cell cycle in cultured  human 
fibroblasts.  We found that cdk2 was activated and  spe- 
cifically localized to the nucleus during  S phase and 
G2.  Microinjection  of afffinity-purified anti-cdk2  anti- 
bodies but not of affinity-purified anti-cdc2  antibodies, 
during  G1,  inhibited  entry into  S phase.  The  specific- 
ity of these effects was demonstrated  by the fact that a 
plasmid-driven  cdk2 overexpression counteracted  the 
inhibition.  These results demonstrate  that the cdk2 
protein  kinase  is involved in the activation  of DNA 
synthesis. 
T 
HE cdc2 protein kinase is thought to be an essential 
cell-cycle regulator  of all  eukaryotic  cells.  Genetic 
and biochemical studies had shown that in yeast, this 
proteirr kinase (called cdc2 in Schizosaccharomyces pombe 
and  CDC28  in Saccharomyces cerevisiae) is  required  for 
both  S  phase  and  mitosis  (for  review  see  Forsburg  and 
Nurse, 1991). It was therefore assumed that cdc2 might play 
a role in both initiation of S phase and entry into mitosis in 
higher eukaryotes as well.  But it now seems that in mam- 
malian  cells cdc2 may only be involved in controlling  the 
G2/M  transition.  Biochemical  studies in human  cells and 
other species have demonstrated that cdc2, in a complex with 
its major regulatory subunit, cyclin B, is activated at the end 
of the G2 phase of the cell cycle, being responsible for trig- 
gering and maintaining cells in mitosis (Draetta and Beach, 
1988;  Pines and Hunter,  1989).  Furthermore,  it has been 
found that inhibition of the cdc2 function by anti-cdc2 anti- 
body microinjection prevents cell division, without affecting 
DNA synthesis (Riabowol et al., 1989). In addition, a mouse 
cell line  (FT210)  (Th'ng  et al.,  1990)  (Hamaguchi  et al., 
1992) carrying  a temperature-sensitive  cdc2 mutation,  ar- 
rests only in G2 at the restrictive temperature. 
In human cells, a protein, originally called p60, was shown 
to be associated with a cell cycle-dependent histone H1 ki- 
nase activity present in interphase  (Giordano et al.,  1989). 
This protein was subsequently identified as human cyclin A 
(Pines and Hunter,  1990; Wang et al.,  1990) and was shown 
to be associated with cdc2 (Giordano et al.,  1989) but also 
with a related protein (Pines and Hunter, 1990). A screening 
devoted to the identification of this and other cdc2-1ike spe- 
cies in human cells led to the cloning of a family of cdc2- 
related kinases (Myerson et al., 1992). Among them, cyclin- 
dependent kinase 2  (cdl~) 1 is one of the two new kinases 
identified that are able to rescue yeast cdc2/28 defects (El- 
ledge and Spottswood,  1991;  Ninomiya-Tsuji et al.,  1991) 
(Tsai et al.,  1991; Meyerson et al.,  1992). It shares '~60% 
identity with cdc2 and is homologous (89%  identity at the 
amino acid level) to a protein, called Eg-1, that had been pre- 
viously identified as the product of a polyadenylated mRNA 
in unfertilized Xenopus eggs, but not in early embryos (Paris 
et al.,  1991).  Human cdk2 mRNA expression increases be- 
fore that of cdc2 in cells stimulated to enter the cell cycle 
(Ninomiya-Tsuji et al.,  1991; Elledge et al.,  1992). The first 
identified and the major cyclin partner of cdk2 was shown 
to be cyclin A (Tsai et al., 1991; Elledge et al., 1992; Pagano 
et al., 1992c; Rosenhlatt et al., 1992). In human cells, ldnase 
activity associated with cyclin A-cdk2 is present in S and in 
G2 (Pagano et al.,  1992a; Pagano et al.,  1992c; Rosenblatt 
et al., 1992), whereas the cyclin A-cdc2 complex is activated 
only in G2 (Pagano et al.,  1992c) and cyclin B-cdc2 activity 
is maximal in M phase (Draetta and Beach, 1988). cdk2 also 
forms a complex with other partners:  cyclin E  (Koff et al., 
1991), cyclin D1 and D3 (Xiong et al.,  1992) and cyclin B1 
(Pagano, M., B. R. Franza, Jr., and G. Draetta, unpublished 
results).  Cyclin E-cdk2 kinase is activated in the G1 and S 
phases of the cell cycle (Dulic et al., 1992; Koffet al., 1992). 
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complexes when bound to cdk2. It has been suggested that 
cyclin A  is needed for both DNA replication and mitosis 
since anti-cyclin A  antibody or antisense cyclin A  cDNA 
plasmid microinjections will prevent the entry into S phase 
(Girard et al.,  1991; Pagano et al.,  1992c;  Zindy et al., 
1992) and into mitosis (Pagano et al.,  1992c).  In Xenopus 
extracts, depletion of the endogenous cdk2 protein blocks 
DNA  replication  (Fang  and  Newport,  1991), whereas 
removal of cdc2 does not. All these data suggest that cdk2 
may act earlier in the cell cycle than cdc2. 
Candidate substrates and, more in general, targets for a 
cyclin-dependent kinase acting earlier in the cell cycle than 
cdc2 have been identified. For example, unphosphorylated 
SV-40 large tumor antigen is deficient in promoting DNA 
replication in vitro but it can be phosphorylated and acti- 
vated by a cdc2 kinase in vitro (McVey et al., 1989). Replica- 
tion of the SV-40 DNA in vitro cannot be initiated in extracts 
from G1 cells. Addition of a factor, RF-S, containing an ac- 
tive cyclin-dependent kinase, or addition of purified cyclin 
A  to  G1  extracts  is  sufficient to  start  DNA  replication 
(D'Urso  et al.,  1990).  Cyclin-dependent kinases are also 
able to phosphorylate RP-A replication factor and stimulate 
DNA replication in cell-free SV-40 replication assays where 
the large T antigen is already hyperphosphorylated (Dutta et 
al., 1991; Dutta and Stillmann, 1992). In addition the timing 
of activation of  the cyclin A-cdk2 kinase is in agreement with 
the timing of RP-A phosphorylation in the cell cycle (Dutta 
and Stillmann, 1992). Finally, cdk2 and cyclin A, but not cy- 
clin B, are associated with DNA in the initiation complex 
during replication (Fotedar and Roberts,  1991). 
Recently, an important substrate for cdk2 kinase has been 
identified as the product of the retinoblastoma susceptibility 
gene (pRB).  Purified cdk2 phosphorylates pRB in vitro at 
most of the sites found to be phosphorylated in vivo (Ak- 
iyama et al.,  1992).  In living cells pRB phosphorylation is 
cell cycle dependent and is believed to be essential for cells 
to progress through G1  (for a  review see Cobrinik et al., 
1992).  It has now been shown that ectopically expressed 
pRB arrests cells lacking endogenous pRB, in G0/G1.  Co- 
transfection of cyclin A or cyclin E, but not cyclin B, over- 
comes the pRB-mediated block. Interestingly, these cyclins 
are unable to rescue the block induced by a mutated pRb, 
that  lacks  essential  phosphorylation  sites.  These  results 
strongly suggest that pRB is a key substrate of cdk2/cyclin 
E and/or cdk2/cyclin A (Hids et al.,  1992). 
Both cyclin A-cdk2 and cyclin E-cdk2 complexes physi- 
cally associate with the E2F transcription factor (Mudryj et 
al., 1991; Cao et al.,  1992; Devoto et al.,  1992; Pagano et 
al.,  1992a;  Lees et al.,  1992).  E2F is a  cellular protein 
needed for transcription from the adenoviral E2 promoter in 
infected cells (for a review see Moran, 1991). In addition it 
has been found that several cellular genes involved in cell 
proliferation like c-myc, N-myc, and c-myb (Mudryj et al., 
1990),  cdc2, (Dalton, 1992) and a set of genes involved in 
DNA replication like the DNA polymerase o~ (Pearson et al., 
1991),  the  dihydrofolate reductase  (Blake and  Azizkhan, 
1989) and the thymidine kinase genes (Kim and Lees, 1991) 
have E2F-type binding sites in their promoter regions. E2F 
also associates with pRB, forming a transcriptionally inac- 
tive complex  (Hamel et al.,  1992;  Hiebert et al.,  1992; 
Weintraub et al.,  1992).  The role of cdk2-cyclin A/E in 
regulating E2F-mediated transcription is not clear at pres- 
ent.  Immediate-early proteins of human cytomegalovirus 
activate the promoter of the dihydrofolate reductase gene 
specifically through the E2F sites and at the same time they 
induce the appearance of E2F-cyclin A-cdk2 complex in the 
cell (Wade et al.,  1992).  This suggests that the cdk2-cyclin 
A  kinase plays a  positive role  in  the  activation of E2F- 
dependent transcription. 
There are strong indications that the cdk2-cyclin A com- 
plex is targeted by oncogenic viruses. Human papillomavi- 
rus E7 is able to dissociate complexes between E2F and pRB 
but complexes containing E2F and cyclin A are maintained 
(Pagano et al., 1992b).  In contrast, the Adenovirus EIA on- 
coprotein can dissociate E2F from both cyclin A-cdk2 and 
pRB, thus allowing binding of a potent transcriptional stimu- 
lator, the Adenovirus FA protein, to the E2 promoter (for re- 
view see Pagano and Draetta, 1991; Nevins, 1992). cdk2 and 
cyclin A were also found physically  associated with the prod- 
uct of the adenovirus E1A (Giordano et al., 1991a; Hermann 
et al., 1991; Kleinberger and Shenk, 1991; Tsai et al., 1991), 
with the product of the human papillomavirus 16 E7 (Tom- 
masino et al., 1993) and with the SV-40 large T antigen (M. 
Pagano and G. Draetta, unpublished results). The domains 
in the Adenovirus EIA protein required for oncogenic activ- 
ity are also necessary for binding to cyclin A (Giordano et 
al., 1991b) and pRB (Whyte et al., 1989) and for dissociating 
E2F complexes (Raychaudhuri et al.,  1991). 
The accumulating evidence suggests that in mammalian 
cells cdk2 plays a role in the induction of S phase (through 
phosphorylation of specific  substrates,  e.g.,  pRB,  RP-A, 
and/or association with E2F-related transcription factors). 
In this paper we examined the intracellular localization of  the 
cdk2 protein and the effects of inhibiting its function in vivo. 
Materials and Methods 
lmmunochemistry 
The anti-cdk2 antibodies were generated by injecting rabbits with the pep- 
tide CHPFFQDVTKPVPHLRL,  corresponding to the carboxy terminus of 
the human cdk2 kinase. The cysteine residue was added to couple the pep- 
tide to keyhole limpet hemocyanine according to (Green et al., 1982). Prep- 
aration of anti-cdk2 antibodies was performed as described in (Pagano et 
al.,  1992a).  Anti-peptide immunoglobulins were purified as described in 
(Draetta and Beach, 1988). Briefly, 10 nag of peptide were covalenfly cou- 
pled to 1 g of CNBr-activated Sepharose 4B. 10 ml of immune serum were 
incubated batchwise with 1 ml of cdk2 peptide-Sephamse preequilibrated 
with 50 mM Tris-HC1, pH 7.4,400 mM NaCI, 0.1% NP-40. After overnight 
incubation at 4°C, the Sepharose was poured onto a column and washed 
with 20 ml of equilibration buffer.  10 ml glycine-HCl, pH 2.3, in 0.5-mi 
aliquots, were applied to elute the antibodies. To neutralize the fractions, 
0.025 ml of 1 M Tris-HC1, pH 9.0, were added. Fractions were individually 
checked for purity and specificity before being pooled. The preparation and 
affinity  purification  of  the  anti-cdc2  (generated  against  the  peptide 
CDNQIKKM) and of the anti-cyclin A antibodies have been described pre- 
viously (Draetta and Beach, 1988; Pagano et al.,  1992c). The preparation 
and characterization of the anti-cyclin B will be described elsewhere (Bal- 
din, V., manuscript submitted for publication). The anti-PSTAIR peptide 
antiserum  (generated  against  the  sequence  EGVPSTAIRESLLKE)  was 
kindly provided by E.  Karsenti. 
For microinjection experiments, the antibodies were concentrated in PBS 
by centrifugation using Centricon 10 tubes (Amicon Corp., Danvers, MA). 
Cell Culture and Extract Preparation 
Human  lung fibroblasts, IMR-90,  and human foreskin fibroblasts, Hs68 
(CRL1635),  were obtained from the American Type Culture Collection 
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described (Pepperkok et al., 1991). HeLa cells were obtained from the Cold 
Spring Harbor Laboratory Tissue Culture facility  (Cold Spring Harbor, 
NY) and cultured as previously described (Giordano et al,.  1989). Condi- 
tions for immunoprecipitation have been previously described (Draetta and 
Beach, 1988; Giordano et al.,  1989). Briefly, cell extracts  were prepared 
by addition of 3-5 vul of lysis buffer (50 mM Tris-HCl, pH 7.4, 0.25 M 
NaCI, 0.1% Triton-X100,  1 mM EDTA, 50 mM NaF,  I mM DTT, 0.1 mM 
Na3VO4) to a cell pellet.  The following pmteasa inhibitors were added: 0.1 
mM PMSF,  1 /~g/ml leupeptin,  10 t~g/ml soybean trypsin inhibitor, L-1 
Chior-3-(4-tosylamido)-4 Phenyl-2-butanou (TPCK); 10/~g/rni L-1 Chlor- 
3-(4-tosylamido)-7-amino-2-heptanon-hydrochloride  (TLCK);  1  ttg/ml 
aprotinin. For cell fractionatiou, cell monolayers  were washed twice with 
ice-cold PBS containing 1 mM MgCI2, and then cells were harvested with 
a  rubber policeman and taken up in ice-cold hypotonic buffer  (10 mM 
Hepes,  pH 7.9, 1.5 mM MgCI2,  10 mM KCI,  300 mM sucrose,  1 mM 
EDTA,  0.25 mM EGTA,  1 mM DTT, 0.1 mM Na3VO4 +  0.1% NP-40) 
containing the above listed pmtease inhibitors. After swelling on ice for 10 
rain, plasma membranes were disrupted by repeated pipetting through a Gil- 
son microtip.  Cell breakage was assessed by microscopic observation. The 
samples were  subsequently centrifuged  at 3,000  rpm in an Eppendorf 
micmfuge (Brinkman Instruments Inc., Westbury, NY) for 10 min at 4°C 
to recover a cytoplasmic fraction (supernatant). The pellet was resuspended 
in 1/5 of the starting volume in ice-cold hypertonic buffer (20 mM Hepes, 
pH 7.9, 1.5 mM MgCI2, 0.5 M NaCI, 25% glycerol,  1 mM EDTA,  1 mM 
DTT, 0.1 mM Na3VO4) containing the above listed protease inhibitors. Af- 
ter incubation on ice for 30 rain, the sample was homogenized  in a tight- 
fitting Dounce (15 strokes; Kontes Glass Co., Vineland, NJ). The homoge- 
hate was subsequently centrifuged at 3,000 rpm in an Eppendorf microfuge 
(Brinkman Instruments Inc.) for 10 rain at 4°C to recover a nuclear fraction 
(supernatant). Identical amounts of protein were loaded on the gel for both 
fractions.  Inununobiotting was done as described (Draetta et al.,  1987). 
Proteins were transferred from gels by semi-dry blotting as described in 
(Harlow  and Lane,  1988). 
Kinase Assays 
Kinase reactions were performed as described  (Pageno  et al.,  1992c). 
Briefly, after irnmunoprecipitations,  pellets were incubated for 5 rain at 
30°C in the presence of 50 mM Tris-Cl, pH 7.5, 10 mM MgCI2,  1 mM 
DTT, 50/~M ATE 25 ~tCi 32p-~ATP. Histone HI was added at 0.2 mg/ml. 
The results were expressed in pmoles of phosphate incorporated/rain/rag of 
protein. In our standard conditions,  I  pmul of phosphate incorporated/ 
rain/rag of protein is equivalent to c.a.  30,000 cpm. Nonspecific  activity 
(c.a. 2,000 cpm, obtained with preimmune sera) was subtracted from each 
sample. 
Cell Synchronization 
IMR-90 or HS-68 cells (at c.a. 60% density) were incubated for 3 d in DME 
containing  0.5 % FC S. After this period <1% of the cell population incorpo- 
rated 5-bromo deoxyuridine (BrdU) during an incubation of 24 h, as de- 
tected by immunefluorescence.  This result correlated with cell cycle analy- 
sis by flow cytontetry, demonstrating that in these cultures >95 % of the cells 
presented a 2N DNA content. Progression through the cell cycle, after reac- 
tivation with 20% FCS, was monitored by flow cytometry and [3H]thymi- 
dine or BrdU incorporation, as previously  described (Pepperkok  et al., 
1988b). In the indicated experiments, GO cells were added with 20% FCS 
and 7 h after also with 2 mM hydroxyurea  (or alternatively,  with 5 ~g/ml 
aphidicolin) for 19 h. This treatment allowed to recover cells that were 90% 
arrested in early S-phase with a 2 N DNA content, as assessed by flow 
cytometry.  In the indicated experiment, after a aphldicolin block release 
(4 h) 70% of the HeLa cell population was in S phase, as assessed by flow 
cytometry. 
lmmunofluorescence 
Cell monolayers on coverslips  were rinsed in PBS and fixed for 10 rain in 
methanol/acetone (l:l) at -20°C. Other fixation protocols were used:  im- 
mersion in 3 % paraformaidehyde in PBS for 10 rain at 4°C followed by per- 
meabilization for 4 rain with 0.25% Triton X-100 in PBS; or methanol at 
-20°C with or without subsequent permeabilization with 0.25% Triton. 
The different methods gave comparable results although paraformaldehyde 
treatment masked the spindle stain with anti-cdk2 antibody. Coverslips were 
then washed three times with PBS and incubated overnight at 4°C with the 
first antibodies.  Affinity-purified anti-cdk2 antibodies were used at the final 
concentration of 10 ttg/ml, affinity-purified anti-cdc2 antibodies at the final 
concentration of 6 ~tg/ml. AP~er  three washes in PBS, secondary antibodies 
were  applied.  Secondary  antibodies  were  Texas  red-conjugated  goat 
anti-rabbit IgG (Sigma,  St.  Louis, MO; dilution 1:50) and biotinylated 
horse anti-mouse (Vector Laboratories, Burlingame, CA; dilution 1:150). 
After a l-h incubation with secondary antibodies, ceils were washed again 
three times with PBS and incubated 1 h in the dark with FITC-conjugeted 
streptavidin (Vector Laboratories; dilution 1:100). Finally coverslips were 
washed twice with PBS, rinsed once briefly in distilled water, and mounted 
on glass slides with moviol. BrdU staining is described in the microinjec- 
tion paragraph (see below).  Photographs were taken using a Neofluar 63X 
lens mounted on an Axiopbot Photomicroscope (Carl Zeiss, Oberkochen, 
Germany), on films TMY-400 (Eastman Kodak Co., Rochester, NY). In the 
indicated experiments,  the anti-cdk2  or  anti-cdc2  antibodies were pre- 
incubated with a 500-fuld excess of the respective antigenic peptides and 
before use centrifuged for 2 rain to eliminate immunonggregates that could 
react unspecificaily  with the secondary antibody. 
Microinjection 
Affinity-purified  anti-cdk2  antibodies or  purified  cdc2  antibodies  (3.5 
mg/ml in PBS) were microinjected into the cytoplasm or directly into the 
nuclei of the cells with an automated microinjection system  (AIS; Carl 
Zeiss) as described previously  (Ansorge and Pepperkok,  1988; Pepperkok 
et ai., 1990). Using this system the percentage of successfully microinjected 
cells was over 90% for cytoplasmic  and 85% for nuclear microinjections 
(Pepperkok  et ai., 1988a). Nuclear or cytoplasmic microinjection gave es- 
sentiaily  similar results.  80-130  ceils were  micminjected for each ex- 
perimentai point. DNA synthesis was monitored by adding BrdU (Sigma; 
final concentration 100 ~tM) for different times (see text) before fixing the 
cells.  At each time point, plates were washed once with PBS, fixed for 5 
rain with methanol at 4°C, washed again three times with PBS, and then 
stained as previously described (Sorrentino et al., 1990). Briefly, cells were 
incubated with diluted (1:100) Texas red-labeled donkey anti-rabbit immu- 
noglobulins (Amersham Corp., Arlington Heights,  IL), and then washed 
and incubated for 10 rain with 1.5 M HCI and stained with monoclonal anti- 
BrdU  (Partec;  dilution  1:50)  followed  by  a  FITC-conjugated  rabbit 
anti-mouse antibody (Sigma; dilution 1:100). Cells were finally washed for 
5  min in PBS containing Hcechst 33258  (Sigma;  final  concentration 1 
~g/mi) and mounted on glass slides with moviul.  All antibody reactions 
were carried out at room temperature for 30 rain. 
The CMV-cdk2  expression vector was obtained by inserting the entire 
sense oriented open-reading frame of the human cdk2 eDNA in the pX- 
plasmid (Tsai et ai., 1991) (Superti-Furge et al., 1991). Both CMV-cdk2 and 
the pX-plasmid alone were purified by cesium chloride centrifugation and 
injected at a concentration of 100 ng/~l. In the indicated experiments,  the 
anti-cdk2 antibodies were pre-incubated with a 500-fold excess of the cdk2 
or cdc2 antigenic peptide and prior to use, centrifuged for 2 rain to eliminate 
immunoaggregates  that could obstruct the microinjector capillaries. 
Results 
Specificity of  Antibodies to Human cdk2 and cdc2 
To perform functional  studies on the role of cdk2 in the hu- 
man cell cycle, we first characterized  the antibodies  to be 
used. We previously described the generation  of polyclonal 
antibodies to the carboxy-terminal  regions of cdc2 and cdk2 
(Draetta and Beach,  1988; Pagano et al., 1992a),  that con- 
tain unique sequences not present in other cdc2-1ike proteins 
(Meyerson  et  al.,  1992).  The  antibodies  were  affinity 
purified  on peptide-Sepharose columns,  and  their  purity 
assessed by SDS-PAGE and Coomassie stain  (Fig.  1 A). 
Cell extracts from non-immortalized  human lung fibroblasts 
(IMR90) or HeLa cells were analyzed by SDS-PAGE and im- 
munoblotting with these anti-cdk2 or anti-cdc2 affinity-puri- 
fied antibodies  (Fig.  1 B). The anti-cdk2  antibodies  specifi- 
cally recognized  cdk2, while the anti-cdc2  antibodies only 
recognized  odc2, by immunoblotting  or by immunoprecipi- 
tation  (Pagano et al.,  1992b).  Immunoreactivity was abol- 
Pagano et al. G1/S Transition Regulation by cdk2  103 Figure L Purity and specificity of anti-cdk2 and anti-cdc2 antibod- 
ies. (A) Lane 1, afffinity-purified  rabbit anti-cdk2 antibodies, 20 tzg; 
lane 2, affinity-purified  rabbit anti-cdc2 antibodies, 20 #g; lane 3, 
relative molecular weight markers. Proteins electrophoresed  through 
a 12.5% SDS-PAGE were visualized by staining with Coomassie 
blue. (B) Immunoblots. Lane 1, [35S]methionine  labeled in vitro- 
translated cdc2 marker;  lane 2  [ass]methionine labeled in vitro- 
translated cdk2 marker; lane 3, 100/~g HeLa extract; lane 4, 100 
/~g IMR-90 extract; lane 5, [35S]methionine  labeled in vitro-trans- 
lated cdk2 marker; lane 6, [35S]methionine  labeled in vitro-trans- 
lated cdc2 marker; lane 7,  100/xg HeLa extract; lane 8,  100 #g 
IMR-90 extract; lanes 1-4, immunoblotting with affinity-purified 
anti-cdk2;  lanes 5-& immtmoblotting with afffinity-purified  anti- 
cdc2. (C) Immunoprecipitations and immunoblotting. Lane 1, im- 
munoprecipitation  with  anti-cdc2,  lane 2,  immunoprecipitation 
with anti-cdk2; lane 3, cdk2 marker in vitro translated; lane 4, cdc2 
marker  in  vitro  translated;  immunoblotting with  anti-PSTAIR 
antibodies. 
ished after preincubation of the antibodies with the respec- 
tive antigenic peptide (data not shown and see Fig. 3, B and 
D). The anti-cdc2 antibody recognized a Mr 34,000peptide 
and minor additional upshifted bands (Fig.  1 B, lanes 7 and 
8). The anti-cdk2 antibodies recognized a Mr 35,000 and a 
Mr  33,000  peptide  (Fig.  1 B,  lanes  3  and  4).  We  could 
directly compare the migration of these species, after immu- 
noprecipitation with anti-cdk2 or anti-cdc2 antibodies,  by 
blotting with anti-PSTAIR, an antiserum raised against the 
16 amino acid-stretch EGVPSTAIREISLLKE common to 
both cdk2 and cdc2 (Fig.  1 C).  Three distinct bands were 
detected: the 34-kD cdc2 (lane/),  the 35- and the 33-kD 
cdk2  forms  (lane  2),  the  35-kD  comigrating  with  the  in 
vitro-translated  cdk2  (lane  3)  and  the  33-kD  migrating 
slightly faster than the dephosphorylated form of cdc2. The 
33-kD  cdk2  band  was  the  predominant  form  found  as- 
sociated with cyclin A (data not shown). It corresponds to 
the  33-kD protein present in  cyclin A-immunocomplexes 
originally described by (Giordano et al.,  1989) and (Pines. 
and Hunter, 1990). This form of cdk2 is generated from the 
higher migrating 35-kD band as a result of phosphorylation 
of threonine 160 (Gu et al.,  1992). 
cdk2 and cdc2 in Cells Stimulated to Reenter the 
Cell Cycle 
IMR-90 cells are non-transformed, non-immortalized cul- 
tured human diploid lung fibroblasts that can be arrested in 
GO by serum deprivation. After culturing for 3 d in the ab- 
sence of serum, 95% of the cells showed a 2n DNA content 
by flow cytometry and <1% of the cell population incorpo- 
Figure 2. cdk2 and cdc2 kinases in human cells stimulated to re- 
enter the cell cycle. GO cells were reactivated and sampled at the 
indicated intervals. (A and B) DNA synthesis was monitored by 
measuring [3H]thymidine  incorporation. Histone H1 ldnase activi- 
ties were measured after immunoprecipitation with antibodies to 
the indicated proteins. The values in A represent the mean (+SE) 
of two independent experiments. The maximal level of kinase ac- 
tivity corresponds to 1.2, 1.9, 0.7, and 1.2 pmol phosphate incor- 
porated per min per mg of protein with anti-cdk2, anti-cdc2, anti- 
cyclin A, and anti-cyclin B, respectively. (C) cdk2 and cdc2 protein 
levels in cells stimulated to grow. 100 #g of total proteins from 
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(A) IMR-90 cells stained with affinity-purified  anti-cdk2 antibod- 
ies. (B) IMR-90 cells stained with affinity-purified  anti-cdk2 anti- 
bodies preincubated with the antigenic peptide. (C) IMR-90 cells 
stained with affinity-purified anti-cdc2  antibodies.  (D) IMR-90 
cells  stained with affinity-purified anti-cdc2  antibodies preincu- 
bated with the antigenic peptide. (E) Immunoblots. cyclin A and 
cdk2 in cytoplasmic (lanes 1, 3, 5, and 7) and nuclear (lanes 2, 4, 
6, and 8) fractions prepared as described in Materials and Methods, 
in absence (lanes 1, 2, 5, and 6) or in presence (lanes 3, 4, 7, and 
8) of detergent (0.1% NP-40). 100/~g of total proteins from both 
fractions were loaded per lane. (Lanes 1-4) Samples from asyn- 
chronous  cells.  (Lanes 5-8) Samples from aphidicolin-arrested 
cells. Proteins were transferred from gels and immunoblotted with 
the antibodies to the indicated proteins. Bar, 10/zm. 
rated BrdU during a 24-h-incubation period (Pepperkok et 
al., 1988b). Arrested cells were stimulated by serum readdi- 
tion and monitored for a period of 28-36 h. Cells started to 
synthesize DNA,  as  monitored by thymidine (Fig.  2)  or 
5-bromo deoxyuridine (BrdU) (Fig. 8, upper panel) incorpo- 
ration, approximately 16 h  after serum addition.  By 24 h 
about 80% of the cells had incorporated BrdU (Fig. 8, upper 
panel). 
We analyzed the levels of cdk2 and cdc2 after ceils had 
been stimulated to re-enter the cell cycle. The cdk2 and cdc2 
protein levels were determined by immunoblotting (Fig. 2 
C). Following serum readdition the overall amount of cdk2 
and of cdc2 protein gradually increased. This was compara- 
ble to the increasing abundance observed for cdc2 after stim- 
ulation  of  rat  epithelial  cells  and  of  mouse  fibroblasts 
IMR-90 lysates, sampled as in A and B, were loaded per lane. Pro- 
teins were transferred from gels and immunoblotted with the anti- 
bodies to the indicated proteins. (A) o, cdk2 kinase; o, cycA  ki- 
nase; -~, DNA synthesis. (B) o, cdc2 kinase; o, cycB kinase; -z~-, 
DNA synthesis. 
(Draetta et al., 1988) (Lee et al., 1988). The cdk2 and cdc2 
levels continued to increase until 28 hrs after stimulation, 
and then remained constant. The 33k phosphorylated form 
of cdk2 was not present in GO and in early G1. 
The histone HI kinase activity associated with cdk2 was 
high in S phase and G2 cells, and it preceded the activation 
of the cdc2 kinase (Fig. 2, A and B). G1 cells (12 hrs after 
reactivation) contained 20-25 % of the maximal cdk2 activ- 
ity. We also monitored the kinase activity associated with cy- 
clin A and B (Fig. 2, A and B); the former giving a profile 
similar to the one obtained for cdk2 and the latter similar to 
the one obtained for cdc2. It is interesting to note that in all 
our experiments, the cdk2-associated activity in late G1 and 
at the onset of S-phase was  higher than the cyclin A  as- 
sociated activity. This is most probably due to the fact that 
during this time cdk2 forms an active kinase with cyclin E 
(Dulic et al.  1992; Koff et al.,  1992). 
Subcellular Localization of  cdk2 
Using indirect immunofluorescence techniques we studied 
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munofluorescence signals detected with anti-cdk2 (Fig. 3 A) 
and anti-cdc2 (Fig.  3  C) antibodies were found to be dis- 
tributed in both the nucleus and the cytoplasm (in addition 
to the shown methanol-acetone fixation, we obtained similar 
results  by  using  other  fixation  procedures  described  in 
Materials and Methods, data not shown).  Immunofluores- 
cence signals were completely abolished after preincubation 
of the antibodies with the respective antigenic peptide (Fig. 
3, B and D). The results of a subcellular fractionation indeed 
showed that cdk2 was distributed between the nuclear and 
the cytosolic compartments whereas cyclin A was predomi- 
nantly associated with the nuclear fraction (Fig. 3 E). In the 
nuclear fraction, both the 35 and the 33-kD forms of cdk2 
were present. In the cytosolic fraction, we detected only the 
35 kD in asynchronous cells and both forms in cells arrested 
in  S  phase with aphidicolin.  Interestingly, in aphidicolin- 
arrested cells, most of the cdk2 was found in the nucleus, 
probably as result of its association with cyclin A. The cyto- 
plasmic cdk2 was found to increase upon addition of deter- 
gent (0.1% NP-40) (Fig. 3 E, compare in the bottom panel, 
lanes 3 and 7 with I and 5), suggesting that a subpopulation 
of the protein was readily extracted upon nuclear membrane 
dissolution. In Fig. 4  a  series of panels showing cdk2 im- 
munofluorescence in the cell cycle is presented. Cells were 
synchronized by serum starvation,  restimulated,  and ana- 
lyzed at different times. In IMR-90 cells arrested in GO by 
serum starvation, the cdk2-associated immunofluorescence 
signals  were very low,  barely exceeding background level 
(Fig. 4 A). No BrdU incorporation was observed in the same 
cells (Fig. 4 B). During progression through G1, we did not 
observe any significant change in the cdk2 immunofluores- 
cence pattern as compared to GO (data not shown). In con- 
trast, as cells entered S phase, cdk2 started to be detected 
in the nucleus paralleling the BrdU incorporation and the cy- 
clin A nuclear stain, although in '~15% of the cells the nu- 
clear cdk2 stain was detected in the absence of cyclin A stain 
(data not shown). Throughout S phase (24 h after restimula- 
tion), a clear cdk2-specific immunoreactivity was detected 
in the nucleus (Fig. 4 C) indicating that the majority of the 
cdk2 localized to the nuclear compartment during DNA syn- 
thesis (Fig. 4 D). Similar results were obtained also in HeLa 
cells synchronized in S phase by aphidicolin block release 
(Fig. 4, K and L). Between 28 and 32 h  after IMR-90 re- 
stimulation, most of the cells (70-80%) that were no longer 
incorporating BrdU, (Fig. 4, F and H, respectively), still re- 
tained quite strong cdk2 nuclear signal (Fig. 4 E) while a mi- 
nor fraction showed a more pronounced cytoplasmic signal 
(Fig. 4 G). The position of these ceils in G2 phase of the ceil 
cycle was verified by co-staining with mAbs against human 
cdc2 (Lukas et al.,  1992) that revealed the G2-specific cen- 
trosome-associated  staining  (not  shown).  Using  our  re- 
agents, we never observed cdk2 association with the centro- 
somes, in contrast to cdc2 (data not shown; and Bailly et al., 
Figure  4.  edk2  immunoflu- 
orescence  during  the  cell 
cycle.  (.4, C,  E,  G,  and  I) 
Time course of cdk2 immuno- 
fluorescence in synchronized 
[MR-90 cells. (A and B) Qui- 
escent ceils. (C and D) 24 h 
after reactivation. (E and F) 
28 h after reactivation. (G, H, 
I, and J) 32 h after reactiva- 
tion. (K and L) HeLa cells 4 h 
after release from aphidicolin 
block. (.4, C, E, G, I, and K) 
Staining with affinity-purified 
anti-cdk2  antibody. (8, D, F,, 
H, J, L): BrdU incorporation 
detected by mAb anti-BrdU, 
monitoring  DNA  synthesis. 
Bar,  10 ~m. 
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1992c). Interestingly, during mitosis most of the metaphase 
cells presented in  cdk2  co-localized with  mitotic  spindle 
(Fig. 4 I) similarly to cyclin B1  (Pines and Hunter,  1991), 
but in contrast to cyclin A that only stained a minor fraction 
(5-10%) of the metaphase spindles (Pagano et al.,  1992c). 
Antibodies to cdk2 Injected in G1 Inhibit S-phase 
The localization of cdk2 in the nucleus (Fig. 4 C), its associ- 
ation with cyclin A, D, and E, the timing of activation of the 
cdk2 kinase (Fig. 2 A; and Pagano et al.,  1992a) prompted 
us to test whether cdk2 was needed for the occurrence of S 
phase. IMR-90 cells were arrested in GO by serum depriva- 
tion. Cells were reactivated and afffinity-purified anti-cdk2 or 
anti-cdc2 were microinjected into the cells during the G1 
phase of the cell cycle (11-12 h after serum readdition). In 
each experiment typically 80-130 cells were microinjected 
within 10 min using a computer automated microinjection 
system (Ansorge and  Pepperkok,  1988;  Pepperkok et al., 
1988a). BrdU was added at 20 h after the reactivation, and 
then at 24 h, cells were fixed and double stained for the in- 
jected antibodies and incorporation of BrdU.  The nuclear 
staining for BrdU incorporation varied according to the posi- 
tion of the cell in S phase (Fox et al., 1991). Cell nuclei with 
a uniform and bright staining and those containing more than 
20 bright spots (cell just entering S phase) were scored as 
BrdU positive. Microinjection in G1 cells of anti-cdk2, but 
not of anti-cdc2 antibodies,  inhibited DNA synthesis. The 
results of one experiment are shown in Fig. 5. In Fig. 6 (first 
two columns) quantitative data from three different experi- 
ments are shown.  Similar results were also obtained upon 
microinjection of non-immortalized human foreskin (Hs68) 
fibroblasts  with  anti-cdk2  antibodies  (data  not  shown). 
When the anti-cdk2  antibodies  were incubated with anti- 
genic  peptide  before  microinjection  (see  Materials  and 
Methods) only a slight (10%) inhibition of BrdU incorpora- 
tion was  observed (Fig.  6,  column 3),  demonstrating that 
DNA synthesis inhibition is in fact due to the specific anti- 
bodies and not to a toxic component present in the antibody 
preparations. Incubation of anti-cdk2 antibodies with cdc2 
antigenic peptide did not prevent DNA synthesis inhibition 
(data not shown). To further test the specificity of the anti- 
cdk2 antibodies we attempted to counteract their effect with 
a plasmid expressing cdk2 under the control of cytomegalo- 
virus promoter, cdk2 protein was highly expressed as moni- 
Figure 5. Microinjection and immunostaining of IMR-90 cells. IMR-90 cells were injected, incubated 4 h with BrdU, fixed, and processed 
for immunofluoreseence as described in Materials and Methods. (A) shows cells injected with anti-cdk2 antibody and immunostalned with 
Texas red-conjugated anti-rabbit antibody. (B) The same field stained with anti-BrdU antibody and FITC-conjugated anti-mouse antibody. 
(C) Contains cells injected with anti-cdc2 antibody and immunostained with Texas red-conjugated anti-rabbit  antibody. (D) The same 
field stained with anti-BrdU antibody and FITC-conjugated anti-mouse antibody. Arrows in B and D indicate the position of the injected 
cells shown respectively in A and C. Bar, 10/~m. 
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peptide  pedk2 
HU-treated  cells 
anti-cdkZ  anti-cde2 
Figure 6. Effect of microinjecting anti-cdk2 and anti-cdc2 antibod- 
ies on DNA synthesis. (Left) For each experiment 80-130 IMR-90 
cells were injected 11-12 h after serum readdition (Gl-cells) with 
the indicated antibodies in absence or in presence of cdk2 antigenic 
peptide or cdk2 expression vector (pcdk2). At 24 h after reactiva- 
tion, cells were fixed and processed for immunofluorescence as de- 
scribed in Materials and Methods. Cells were labeled with BrdU 
for 4 h before fixation. The first two columns represent the mean 
(+SE) of three  independent experiments.  (Right) About  80-130 
IMR-90 cells blocked in S-phase with hydroxyurea (HU-treated 
cells) were injected. Cells were washed three times, incubated in 
presence of BrdU and 4 h later fixed and processed for immuno- 
fluorescence as described in Materials and Methods. BrdU positive 
cells were scored as detailed in the results.  Percent of inhibition 
BrdU incorporation was calculated as (IN -  I]/N) x  100, where 
N is the percentage of BrdU incorporation in non-injected cells and 
I is the percentage  of BrdU  in cells microinjected  with affinity- 
purified anti-cdk2 antibodies  or affinity-purified anti-cdc2  anti- 
bodies. The obtained numerical value is independent of  possible ex- 
perimental variations in the number of BrdU positive cells that had 
not been injected. In each experiment about 100 injected cells (and 
corresponding  number of non-injected cells) were counted. 
1  O0 
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Figure 7. S phase inhibition by anti-cdk2 antibodies is reversible. 
Time course of DNA synthesis after microinjection of affinity-puri- 
fied anti-edk2 or affinity-purified anti-ode2 antibodies in IMR-90 
cells. GO cells were reactivated with 20% serum and microinjeeted 
12 h after. DNA synthesis was monitored  by adding BrdU in the 
last 4 h of culture followed by immunostaining with anti-BrdU and 
FITC-conjugated  anti-mouse antibodies  at the  time points  indi- 
cated in the figure. Injected cells were detected by staining with 
Texas red-labeled anti-rabbit immunoglobulins. DNA synthesis in 
the surrounding cells was also monitored, o, Affinity-purified anti- 
cdk2 injected; e, affinity-purified anti-cdc2 injected; a, surround- 
ing cells. 
tored by immunofluorescence techniques (Pepperkok R., V. 
Baldin, and G. Draetta, unpublished results). Coinjection of 
anti-cdk2 antibodies and cdk2 plasmid resulted in 21% of in- 
hibition of BrdU incorporation (Fig. 6, column 4) compared 
to 63 % in cells injected with anfi-cdk2 antibodies and a con- 
trol plasmid in the  same experiment.  The effects of cdk2 
overexpression on cell-cycle progression are currently under 
study in our laboratory. Microinjection of anti-cdc2 antibod- 
ies was, as expected, effective in blocking cell division (data 
not shown). 
In a kinetic study, at various times after microinjection, 
IMR-90 cells were pulse labeled for 4 hr with BrdU, fixed, 
and then the labeled cells were counted (Fig.  7).  Up to 28 
h a clear inhibition of DNA synthesis was observed in cells 
injected with anti-cdk2. Again, cells injected with anti-cdc2 
were not delayed in their progression into S phase. Interest- 
ingly, by ,o28 h after reactivation, cells slowly recovered and 
started to synthesize DNA, demonstrating that the antibod- 
ies were not toxic to the ceils and that their injection resulted 
in a delay rather than in a block. This could be a consequence 
of the  immunocomplexes  being  metabolized  by  the  cell 
(while cdk2  synthesis continues  during  S  and G2 phases, 
data not shown) and/or of an escape from the block through 
the activation of a substitutive pathway (see Discussion). Our 
data clearly indicate that inhibition of cdk2 function in G1 
inhibits the occurrence of S phase in human cells. 
DNA Replication Is Not Inhibited by Antibodies to 
cdk2 When Injected during S-phase 
To pinpoint the time at which the cdk2 function is required 
for cell-cycle progression, IMR-90 cells were injected with 
anti-cdk2 or anti-cdc2 antibodies in GO or at distinct times 
after serum readdition. At each time point, cells were micro- 
injected and then BrdU added.  All the samples were then 
fixed 24  h  after  reactivation  and  stained  (as  specified in 
Materials and Methods).  In the non-injected cells, S-phase 
progression was monitored by BrdU incorporation (Fig.  8, 
top). Injections up to  16 h  after reactivation resulted in a 
strong inhibition of DNA synthesis; at later times the efficacy 
of the treatment on DNA replication dramatically decreased 
(Fig. 8, bottom). Similar evidence came from microinjection 
experiments performed in the presence of hydroxyurea, which 
arrests cells at the beginning of S phase: quiescent cells were 
re-fed with serum and then after 7 h hydroxyurea was added. 
After a further 19-h incubation they were microinjected with 
anti-cdk2 or anti-cdc2  antibodies,  released from hydroxy- 
urea and added with BrdU. After 4 h cells were fixed and im- 
munostained.  No inhibition of DNA synthesis was detected 
(Fig. 6, right). These results suggest that cdk2 plays an im- 
portant role at the G1/S boundary. 
Discussion 
Studies in yeast have contributed a wealth of information on 
how eukaryotic cells control their division cycle, by identify- 
ing a protein phosphorylation cascade that leads to the acti- 
vation of a single kinase, cdc2/CDC28, which is ultimately 
responsible for leading ceils through the cell cycle. When 
comparing yeast cell cycle regulators to the system operating 
in higher eukaryotes it is clear however that the molecular 
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Figure 8. Dependence of the DNA synthesis inhibition on the time 
point of injection of antibodies. (Top) IMR-90 cells were arrested 
in GO by serum deprivation. After reactivation the cells were incu- 
bated for4 h with BrdU at the indicated times and then fixed and 
stained with anti-BrdU antibodies. The graphic indicates the per- 
centage of cells that have incorporated BrdU from two independent 
experiments (+SE). Each value represents at least 200 cells/experi- 
ment. (Bottom) Cells were reactivated  and microinjected  at the indi- 
cated times with the indicated affinity-purified  antibodies. BrdU 
was applied just after microinjection. 24 h after serum stimulation 
all the samples were fixed and immunostaining was performed as 
described in Materials and Methods. Percent of DNA synthesis in- 
hibition (-I-SE) from two independent experiments was calculated 
as in Fig. 7.  o, Affinity-purified  anti-cdk2 injected; e, affinity- 
purified anti-cdc2 injected. 
events seem to have evolved from a basic module to a much 
more complex network, which involves multiple cdc2-1ike 
proteins. In this paper we have analyzed the role of cdk2, a 
cdc2 homolog, in cultured human fibroblasts (IMR-90) reen- 
tering the cell cycle. In cycling HeLa cells (Pagano et al., 
1992a)  we previously showed that cdk2 is activated during 
S and G2 phase, coincident with its association with cyclin 
A. Here we show that cdk2 level was very low in quiescent 
IMR-90 cells, it increased between 8 and 28 h postserum ad- 
dition, and then remained constant in cycling cells. The ki- 
nase activity associated with cdk2 was already detectable 
(25 % of the maximal activity measured) in late G1, and then 
it increased during S and G2, peaking 4 h before the cdc2 
kinase activity. The cyclin A-associategl ldnase paralleled the 
cdk2 activity during S and G2, but was lower in G1. This is 
most likely due to the association of cdk2 with cyclin E 
(Dulic et al.,  1992; Koff et al.,  1992).  The phosphorylated 
33-kD form of cdk2 appeared when cells reached the G1-S 
transition and strongly decreased by 32 h, in parallel with 
the decreasing kinase activity. This downshift from 35- to 
33-kD form has been shown to be due to threonine 160phos- 
phorylation but the 33 kD also contains phosphotyrosine 15. 
Thus, this band can represent either the double tyrl5 and 
thrl60 phosphorylated (inactive) form or the single thrl60 
phosphorylated (active)  form of cdk2 (Gu et al.,  1992). 
cdk2 was localized predominantly to the nucleus during 
late G1 and S phases. During G2, cdk2 staining was both nu- 
clear and cytoplasmic. Throughout mitosis cdk2 appeared 
associated with the mitotic spindle.  This last result could 
reflect our findings that a minor fraction of cdk2 is associated 
with cyclin B. Indeed, during mitosis, only 5-10%  of the 
metaphase cells show cyclin A staining colocalizing with the 
mitotic spindle (Pagano et al., 1992c) whereas cyclin B anti- 
bodies stain most metaphase spindles (Pines and Hunter, 
1991). 
Upon microinjection of anti-cdk2 antibodies in G1 cells, 
entry into S phase was inhibited. Similar results had been ob- 
tained  with  anti-cyclin A  antibodies  in  different systems 
(Girard et al.,  1991; Pagano et al.,  1992c;  Zindy et al. I, 
1992). An important control was given by injections of anti- 
cdc2 peptide antibodies. These antibodies were incapable of 
inhibiting S phase, while they prevented entry into mitosis, 
and consequently cell division. This demonstrated the speci- 
ficity of our assays and established a good correlation be- 
tween the biochemical activities measured in extracts made 
from synchronized ceils and the role played by each of these 
kinases in the cell cycle. A function for cdc2 in the G1/Stran- 
sition had been proposed in T lymphocytes (Purakawa et al., 
1990)  and in Burkitt lymphoma cells  (Marracmo  et al., 
1992).  We cannot really exclude that in lymphocytes, or 
other cell types, cdc2 might play a role in entry into S phase. 
In addition to our findings, it has been shown that in rat 
fibroblasts, microinjection of different antibodies to cdc2 did 
not have  any effect on DNA  synthesis (Riabowol et al., 
1989). 
The kinetics of inhibition obtained by microinjecting cdk2 
antibodies at different times after serum addition to quies- 
cent cells showed that, to obtain an inhibitory effect, it was 
necessary to  microinject antibodies before the  start of S 
phase. Similarly, the anti-cdk2 microinjections were ineffec- 
tive when performed in cells blocked with hydroxyurea in S 
phase, and then released. Taken together, these results sug- 
gest that cdk2 plays an essential role at the G1/S boundary. 
It is possible, however,  that the antibodies, in order to be 
effective,  must capture cdk2 before its interaction with the 
regulatory subunits or with one or more targets. When S 
phase is already started, anti-cdk2 antibodies microinjec- 
tions could not interfere with these interactions. 
Since cdk2 associates with different cyclins, it could be 
that one or more of these complexes controls progression 
throughout G1 and entry in S phase, while others regulate 
phenomena occurring during S phase (e.g., participating at 
the assembly of unwinding and replication complexes on the 
DNA replication origins or monitoring the fidelity of DNA 
replication or preventing DNA re-replication) or even later. 
Our experiments monitored the occurrence of DNA synthe- 
sis and cannot distinguish between inhibition of  each of  these 
complexes.  The possibilities  that cdk2  might also play a 
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laboratory. 
The discovery of multiple cdc2-1ike proteins and multiple 
cyclins, and the evidence that each of these molecules can as- 
sociate with more than one partner might reflect the need for 
the  cell to  establish  that all  of the  events necessary  for 
progression through each phase of the cell cycle are properly 
accomplished.  On the other hand, it is possible that some of 
these complexes have redundant functions, each working in 
response  to specific  environmental  functions,  but able to 
substitute for one another when needed. We believe that anti- 
body and antisense microinjection experiments will allow us 
to  determine  the  role  played by  each  of  these  cyclin- 
dependent kinases in the cell cycle. 
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